The Cockayne syndrome group B DNA repair protein as an anti-cancer target.

Y. Lu, Sridhar Mani, E. R. Kandimalla, D. Yu, S. Agrawal, J. C. States, D. B. Bregman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cells from individuals with Cockayne syndrome (CS) have a defect in transcription-coupled DNA repair (TCR), which rapidly corrects certain DNA lesions located on the transcribed strand of active genes. Despite this DNA repair defect, individuals with CS (of which there are two complementation groups, CSA and CSB) do not demonstrate an elevated incidence of cancer. Recently, we demonstrated that disruption of the CSB gene reduces the spontaneous tumor rate in cancer predisposed Ink4a/ARF-/- mice as well as causing their embryo fibroblasts to proliferate more slowly and be more sensitive to UV-induced apoptosis. In the present study we characterized phosphorothioate backbone antisense oligodeoxynucleotides (AOs) that reduced the levels of CSB mRNA in A2780/CP70 ovarian carcinoma cells. The AOs caused the cells to proliferate more slowly and made them more sensitive to either cisplatin or oxaliplatin. The AOs also enhanced the cytotoxicity of hydrogen peroxide and gamma-radiation, both of which can induce oxidative DNA lesions, which are subject to TCR. The AOs did not potentiate the cytotoxicity of topotecan, which induces DNA strand breaks. Chemically modified (<mixed backbone>) AOs (MBOs) targeting CSB were able to potentiate the anti-tumor effect of cisplatin against A2780/CP70 tumor xenografts formed in nude mice. The MBOs enabled a non-toxic (3 mg/kg) dose of cisplatin to have the same degree of anti-tumor efficacy as a more toxic (5 mg/kg) cisplatin dose. Collectively, these results suggest that the CSB gene product may be viewed as an anti-cancer target.

Original languageEnglish (US)
Pages (from-to)1089-1097
Number of pages9
JournalInternational Journal of Oncology
Volume19
Issue number6
StatePublished - Dec 2001

Fingerprint

Cockayne Syndrome
DNA Repair
Oligodeoxyribonucleotides
Cisplatin
Neoplasms
Proteins
oxaliplatin
Genes
Topotecan
DNA Breaks
Poisons
DNA
Gamma Rays
Heterografts
Nude Mice
Hydrogen Peroxide
Embryonic Structures
Fibroblasts
Apoptosis
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lu, Y., Mani, S., Kandimalla, E. R., Yu, D., Agrawal, S., States, J. C., & Bregman, D. B. (2001). The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International Journal of Oncology, 19(6), 1089-1097.

The Cockayne syndrome group B DNA repair protein as an anti-cancer target. / Lu, Y.; Mani, Sridhar; Kandimalla, E. R.; Yu, D.; Agrawal, S.; States, J. C.; Bregman, D. B.

In: International Journal of Oncology, Vol. 19, No. 6, 12.2001, p. 1089-1097.

Research output: Contribution to journalArticle

Lu, Y, Mani, S, Kandimalla, ER, Yu, D, Agrawal, S, States, JC & Bregman, DB 2001, 'The Cockayne syndrome group B DNA repair protein as an anti-cancer target.', International Journal of Oncology, vol. 19, no. 6, pp. 1089-1097.
Lu Y, Mani S, Kandimalla ER, Yu D, Agrawal S, States JC et al. The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International Journal of Oncology. 2001 Dec;19(6):1089-1097.
Lu, Y. ; Mani, Sridhar ; Kandimalla, E. R. ; Yu, D. ; Agrawal, S. ; States, J. C. ; Bregman, D. B. / The Cockayne syndrome group B DNA repair protein as an anti-cancer target. In: International Journal of Oncology. 2001 ; Vol. 19, No. 6. pp. 1089-1097.
@article{f5068f3e390a4b79aaaaefaa9e5b7350,
title = "The Cockayne syndrome group B DNA repair protein as an anti-cancer target.",
abstract = "Cells from individuals with Cockayne syndrome (CS) have a defect in transcription-coupled DNA repair (TCR), which rapidly corrects certain DNA lesions located on the transcribed strand of active genes. Despite this DNA repair defect, individuals with CS (of which there are two complementation groups, CSA and CSB) do not demonstrate an elevated incidence of cancer. Recently, we demonstrated that disruption of the CSB gene reduces the spontaneous tumor rate in cancer predisposed Ink4a/ARF-/- mice as well as causing their embryo fibroblasts to proliferate more slowly and be more sensitive to UV-induced apoptosis. In the present study we characterized phosphorothioate backbone antisense oligodeoxynucleotides (AOs) that reduced the levels of CSB mRNA in A2780/CP70 ovarian carcinoma cells. The AOs caused the cells to proliferate more slowly and made them more sensitive to either cisplatin or oxaliplatin. The AOs also enhanced the cytotoxicity of hydrogen peroxide and gamma-radiation, both of which can induce oxidative DNA lesions, which are subject to TCR. The AOs did not potentiate the cytotoxicity of topotecan, which induces DNA strand breaks. Chemically modified () AOs (MBOs) targeting CSB were able to potentiate the anti-tumor effect of cisplatin against A2780/CP70 tumor xenografts formed in nude mice. The MBOs enabled a non-toxic (3 mg/kg) dose of cisplatin to have the same degree of anti-tumor efficacy as a more toxic (5 mg/kg) cisplatin dose. Collectively, these results suggest that the CSB gene product may be viewed as an anti-cancer target.",
author = "Y. Lu and Sridhar Mani and Kandimalla, {E. R.} and D. Yu and S. Agrawal and States, {J. C.} and Bregman, {D. B.}",
year = "2001",
month = "12",
language = "English (US)",
volume = "19",
pages = "1089--1097",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - The Cockayne syndrome group B DNA repair protein as an anti-cancer target.

AU - Lu, Y.

AU - Mani, Sridhar

AU - Kandimalla, E. R.

AU - Yu, D.

AU - Agrawal, S.

AU - States, J. C.

AU - Bregman, D. B.

PY - 2001/12

Y1 - 2001/12

N2 - Cells from individuals with Cockayne syndrome (CS) have a defect in transcription-coupled DNA repair (TCR), which rapidly corrects certain DNA lesions located on the transcribed strand of active genes. Despite this DNA repair defect, individuals with CS (of which there are two complementation groups, CSA and CSB) do not demonstrate an elevated incidence of cancer. Recently, we demonstrated that disruption of the CSB gene reduces the spontaneous tumor rate in cancer predisposed Ink4a/ARF-/- mice as well as causing their embryo fibroblasts to proliferate more slowly and be more sensitive to UV-induced apoptosis. In the present study we characterized phosphorothioate backbone antisense oligodeoxynucleotides (AOs) that reduced the levels of CSB mRNA in A2780/CP70 ovarian carcinoma cells. The AOs caused the cells to proliferate more slowly and made them more sensitive to either cisplatin or oxaliplatin. The AOs also enhanced the cytotoxicity of hydrogen peroxide and gamma-radiation, both of which can induce oxidative DNA lesions, which are subject to TCR. The AOs did not potentiate the cytotoxicity of topotecan, which induces DNA strand breaks. Chemically modified () AOs (MBOs) targeting CSB were able to potentiate the anti-tumor effect of cisplatin against A2780/CP70 tumor xenografts formed in nude mice. The MBOs enabled a non-toxic (3 mg/kg) dose of cisplatin to have the same degree of anti-tumor efficacy as a more toxic (5 mg/kg) cisplatin dose. Collectively, these results suggest that the CSB gene product may be viewed as an anti-cancer target.

AB - Cells from individuals with Cockayne syndrome (CS) have a defect in transcription-coupled DNA repair (TCR), which rapidly corrects certain DNA lesions located on the transcribed strand of active genes. Despite this DNA repair defect, individuals with CS (of which there are two complementation groups, CSA and CSB) do not demonstrate an elevated incidence of cancer. Recently, we demonstrated that disruption of the CSB gene reduces the spontaneous tumor rate in cancer predisposed Ink4a/ARF-/- mice as well as causing their embryo fibroblasts to proliferate more slowly and be more sensitive to UV-induced apoptosis. In the present study we characterized phosphorothioate backbone antisense oligodeoxynucleotides (AOs) that reduced the levels of CSB mRNA in A2780/CP70 ovarian carcinoma cells. The AOs caused the cells to proliferate more slowly and made them more sensitive to either cisplatin or oxaliplatin. The AOs also enhanced the cytotoxicity of hydrogen peroxide and gamma-radiation, both of which can induce oxidative DNA lesions, which are subject to TCR. The AOs did not potentiate the cytotoxicity of topotecan, which induces DNA strand breaks. Chemically modified () AOs (MBOs) targeting CSB were able to potentiate the anti-tumor effect of cisplatin against A2780/CP70 tumor xenografts formed in nude mice. The MBOs enabled a non-toxic (3 mg/kg) dose of cisplatin to have the same degree of anti-tumor efficacy as a more toxic (5 mg/kg) cisplatin dose. Collectively, these results suggest that the CSB gene product may be viewed as an anti-cancer target.

UR - http://www.scopus.com/inward/record.url?scp=0035653492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035653492&partnerID=8YFLogxK

M3 - Article

C2 - 11713576

AN - SCOPUS:0035653492

VL - 19

SP - 1089

EP - 1097

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -